Can-Fite BioPharma Ltd. (CANF)

Market Cap	5.17M -68.4%
Revenue (ttm)	560,000 -16.0%
Net Income	-8.80M
EPS	-8.88
Shares Out	1.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,821
Open	3.780
Previous Close	3.720
Day's Range	3.530 - 3.780
52-Week Range	3.356 - 46.600
Beta	0.04
Analysts	Strong Buy
Price Target	9,750.00 (+270,733.33%)
Earnings Date	Mar 27, 2026

About CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 5
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CANF
• Website: https://www.canfite.com

Financial Performance

In 2024, Can-Fite BioPharma's revenue was $674,000, a decrease of -9.29% compared to the previous year's $743,000. Losses were -$7.88 million, 3.22% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for CANF stock is "Strong Buy." The 12-month stock price target is $9,750.0, which is an increase of 270,733.33% from the latest price.

Price Target

$9,750.0

(270,733.33% upside)

Analyst Consensus: Strong Buy